Eldecalcitol for the treatment of osteoporosis

Drugs of Today

Volumn 48, Issue 3, 2012, Pages 189-196

  Matsumoto, Toshio ^a   Endo, I ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

ED 71; Eldecalcitol; Osteoporosis

Indexed keywords

ALFACALCIDOL; ELDECALCITOL; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

BINDING AFFINITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; TREATMENT INDICATION; VERTEBRA FRACTURE;

ADULT; AGED; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; VITAMIN D;

EID: 84859715529     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.3.1745223     Document Type: Review

References (20)

1. Papadimitropoulos, E., Wells, G., Shea, B. et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Metaanalysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002, 23(4): 560-9. (Pubitemid 34925650)
2. Matsumoto, T., Takano, T., Yamakido, S., Takahashi, F., Tsuji, N. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol 2010, 121(1-2): 261-4.
3. Miyamoto, K., Murayama, E., Ochi, K., Watanabe, H., Kubodera, N. Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position. Chem Pharm Bull (Tokyo) 1993, 41(6): 1111-3. (Pubitemid 23240095)
4. Ono, Y., Watanabe, H., Shiraishi, A. et al. Synthetic studies of vitamin D analogs. XXIV. Synthesis of active vitamin D3 analogs substituted at the 2 beta-position and their preventive effects on bone mineral loss in ovariectomized rats. Chem Pharm Bull (Tokyo) 1997, 45(10): 1626-30. (Pubitemid 27488425)
5. Hatakeyama, S., Nagashima, S., Imai, N. et al. Synthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71). J Steroid Biochem Mol Biol 2007, 103(3-5): 222-6. (Pubitemid 46401295)
6. Abe, M., Tsuji, N., Takahashi, F., Tanigawara, Y. [Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative]. Jpn Pharmacol Ther 2011, 39(3): 261-74.
7. Harada, S., Takeda, S., Uno, A., Takahashi, F., Saito, H. Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J Steroid Biochem Mol Biol 2011, 121(1-2): 281-3.
8. Ritter, C.S., Brown, A.J. Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism. J Cell Biochem 2011, 112(5): 1348-52.
9. Uchiyama, Y., Higuch, I.Y., Takeda, S. et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30(4): 582-8. (Pubitemid 34270495)
10. Tsurukami, H., Nakamura, T., Suzuki, K., Sato, K., Higuchi, Y., Nishii, Y. A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 1994, 54(2): 142-9. (Pubitemid 24046725)
11. de Freitas, P.H., Hasegawa, T., Takeda, S. et al. Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 2011, 49(3): 335-42.
12. Jee, W.S., Tian, X.Y., Setterberg, R.B. Cancellous bone mini-modeling-based formation: a Frost, Takahashi legacy. J Musculoskelet Neuronal Interact 2007, 7(3): 232-9. (Pubitemid 350238151)
13. Cao, Y., Mori, S., Mashiba, T. et al. 1alpha,25-Dihydroxy- 2beta(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora. Bone 2007, 40(1): 132-9. (Pubitemid 44839343)
14. Yamane, K., Okano, T., Kishimoto, H., Hagino, H. Effect of ED-71 on modeling of bone in distraction osteogenesis. Bone 1999, 24(3): 187-93. (Pubitemid 29094560)
15. Harada, S., Kobayashi, Y., Nakamichi, Y. et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2011, Epub ahead of print.
16. Matsumoto, T., Kubodera, N., Group, T.E.-S. 1alpha,25-Dihydroxy-2beta-(3- hydroxypropoxy)vitamin D3 (ED-71): A promising candidate for the treatment of osteoporosis. Proceedings of the 11th Workshop on Vitamin D 2000: 985-92.
17. Matsumoto, T., Miki, T., Hagino, H. et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005, 90(9): 5031-6. (Pubitemid 41262250)
18. Matsumoto, T., Kubodera, N. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 2007, 103(3-5): 584-6. (Pubitemid 46401355)
19. Matsumoto, T., Ito, M., Hayashi, Y. et al. A new active vitamin D(3) analog, eldecalcitol, prevents the risk of osteoporotic fractures - A randomized, active comparator, double-blind study. Bone 2011, 49(4): 605-12.
20. Ito, M., Nakamura, T., Fukunaga, M., Shiraki, M., Matsumoto, T. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 2011, 49(3): 328-34.